RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (MARKET WIRE) -- October 30, 2006 -- Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that it has entered into an agreement with the International Childhood Liver Tumour Strategy Group (known as SIOPEL), a multi-disciplinary group of specialists under the umbrella of the International Society of Pediatric Oncology (SIOP), for the conduct of a Phase III trial of sodium thiosulfate (STS), a drug that Adherex is developing to reduce or prevent hearing loss in children associated with platinum-based chemotherapies. The trial is projected to begin in early 2007.
